Expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR) in thyroid nodular hyperplasia and papillary thyroid carcinoma (PTC)

ABSTRACT Background and objective: Vascular endothelial growth factor (VEGF) is an angiogenic factor that plays important role in tumour growth with ongoing research regarding its role as a prognostic factor and also targeted anti-angiogenic therapeutic agent in thyroid cancer. VEGF is known to hav...

Full description

Saved in:

Bibliographic Details
Main Author:	Razy, Nur Hidayati Mohamad Pakarul
Format:	Thesis
Language:	English
Published:	2017
Subjects:	RC648-665 Diseases of the endocrine glands Clinical endocrinology
Online Access:	http://eprints.usm.my/45422/1/Dr.%20Nurhidayati%20Mohamad%20Pakarul%20Razy-24%20pages.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

id	my-usm-ep.45422
record_format	uketd_dc
spelling	my-usm-ep.454222020-10-22T03:03:15Z Expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR) in thyroid nodular hyperplasia and papillary thyroid carcinoma (PTC) 2017 Razy, Nur Hidayati Mohamad Pakarul RC648-665 Diseases of the endocrine glands. Clinical endocrinology ABSTRACT Background and objective: Vascular endothelial growth factor (VEGF) is an angiogenic factor that plays important role in tumour growth with ongoing research regarding its role as a prognostic factor and also targeted anti-angiogenic therapeutic agent in thyroid cancer. VEGF is known to have high affinity to VEGF receptors such as VEGFR-1 (Flt-1) and VEGFR-2 (KDR) and their co-expression in pathological condition had been demonstrated in previous studies. Papillary thyroid carcinoma (PTC) is the most common differentiated thyroid cancer and studies showed the increasing incidence of carcinoma arising in multinodular goitre (MNG). The aim of the current study to determine the expression of VEGF and VEGF receptors (VEGFR) in thyroid nodular hyperplasia and PTC. Materials and methods: We conducted a cross sectional study based on retrieved paraffinized archival tissue blocks of 113 nodular hyperplasia and 67 PTC from the thyroidectomy specimens from the year of 2003 to 2014.The tissue sections were then stained by immunohistochemistry for VEGF, VEGFR-1 and VEGFR-2. The lymph node involvement and extrathyroid extension also were determined. Results: The mean age of PTC patients was 44.7 ± 15.8years and nodular hyperplasia subjectswere42.2 ± 13.6years. Female gender predominate in both benign nodular hyperplasia and PTC with, 86% (97 out of 113) and 78% (52 out of67) respectively. There was a statistical difference of VEGFR-1 (p=0.028) andVEGFR-2 (p=0.003) expression between nodular hyperplasia and PTC. However, no significant difference of VEGF expression (p=0.576) between both diseases. Co-expression of VEGF and VEGFR-1 was significant in both nodular hyperplasia (p=0.016) and papillary thyroid carcinoma (p=0.03), meanwhile no relevant relationship for VEGF and VEGFR-2 expression (p>0.05). The patients were further divided into young age group (<45 years old) and older age group (≥45 years old). Most of the subjects positive for lymph node metastasis and had extrathyroid extension were female and from older age group. From 15 lymph nodes with metastasis, 60% (9/15) were female and 53% (8/15) from older age group. All two cases that showed extrathyroid extension were from older age group and female. However, there was no significant association (p>0.05) between lymph node status and extrathyroid extension with age groups, gender, VEGF and VEGFR expression. Conclusions: VEGF, VEGFR-1 and VEGFR-2 showed overexpression in both benign thyroid nodular hyperplasia and PTC. The expression of VEGFR-1 and VEGFR-2 more significant in PTC with relevant co-expression of VEGF and VEGFR-1. 2017 Thesis http://eprints.usm.my/45422/ http://eprints.usm.my/45422/1/Dr.%20Nurhidayati%20Mohamad%20Pakarul%20Razy-24%20pages.pdf application/pdf en public masters Universiti Sains Malaysia Pusat Pengajian Sains Perubatan
institution	Universiti Sains Malaysia
collection	USM Institutional Repository
language	English
topic	RC648-665 Diseases of the endocrine glands Clinical endocrinology
spellingShingle	RC648-665 Diseases of the endocrine glands Clinical endocrinology Razy, Nur Hidayati Mohamad Pakarul Expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR) in thyroid nodular hyperplasia and papillary thyroid carcinoma (PTC)
description	ABSTRACT Background and objective: Vascular endothelial growth factor (VEGF) is an angiogenic factor that plays important role in tumour growth with ongoing research regarding its role as a prognostic factor and also targeted anti-angiogenic therapeutic agent in thyroid cancer. VEGF is known to have high affinity to VEGF receptors such as VEGFR-1 (Flt-1) and VEGFR-2 (KDR) and their co-expression in pathological condition had been demonstrated in previous studies. Papillary thyroid carcinoma (PTC) is the most common differentiated thyroid cancer and studies showed the increasing incidence of carcinoma arising in multinodular goitre (MNG). The aim of the current study to determine the expression of VEGF and VEGF receptors (VEGFR) in thyroid nodular hyperplasia and PTC. Materials and methods: We conducted a cross sectional study based on retrieved paraffinized archival tissue blocks of 113 nodular hyperplasia and 67 PTC from the thyroidectomy specimens from the year of 2003 to 2014.The tissue sections were then stained by immunohistochemistry for VEGF, VEGFR-1 and VEGFR-2. The lymph node involvement and extrathyroid extension also were determined. Results: The mean age of PTC patients was 44.7 ± 15.8years and nodular hyperplasia subjectswere42.2 ± 13.6years. Female gender predominate in both benign nodular hyperplasia and PTC with, 86% (97 out of 113) and 78% (52 out of67) respectively. There was a statistical difference of VEGFR-1 (p=0.028) andVEGFR-2 (p=0.003) expression between nodular hyperplasia and PTC. However, no significant difference of VEGF expression (p=0.576) between both diseases. Co-expression of VEGF and VEGFR-1 was significant in both nodular hyperplasia (p=0.016) and papillary thyroid carcinoma (p=0.03), meanwhile no relevant relationship for VEGF and VEGFR-2 expression (p>0.05). The patients were further divided into young age group (<45 years old) and older age group (≥45 years old). Most of the subjects positive for lymph node metastasis and had extrathyroid extension were female and from older age group. From 15 lymph nodes with metastasis, 60% (9/15) were female and 53% (8/15) from older age group. All two cases that showed extrathyroid extension were from older age group and female. However, there was no significant association (p>0.05) between lymph node status and extrathyroid extension with age groups, gender, VEGF and VEGFR expression. Conclusions: VEGF, VEGFR-1 and VEGFR-2 showed overexpression in both benign thyroid nodular hyperplasia and PTC. The expression of VEGFR-1 and VEGFR-2 more significant in PTC with relevant co-expression of VEGF and VEGFR-1.
format	Thesis
qualification_level	Master's degree
author	Razy, Nur Hidayati Mohamad Pakarul
author_facet	Razy, Nur Hidayati Mohamad Pakarul
author_sort	Razy, Nur Hidayati Mohamad Pakarul
title	Expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR) in thyroid nodular hyperplasia and papillary thyroid carcinoma (PTC)
title_short	Expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR) in thyroid nodular hyperplasia and papillary thyroid carcinoma (PTC)
title_full	Expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR) in thyroid nodular hyperplasia and papillary thyroid carcinoma (PTC)
title_fullStr	Expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR) in thyroid nodular hyperplasia and papillary thyroid carcinoma (PTC)
title_full_unstemmed	Expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR) in thyroid nodular hyperplasia and papillary thyroid carcinoma (PTC)
title_sort	expression of vascular endothelial growth factor (vegf) and its receptor (vegfr) in thyroid nodular hyperplasia and papillary thyroid carcinoma (ptc)
granting_institution	Universiti Sains Malaysia
granting_department	Pusat Pengajian Sains Perubatan
publishDate	2017
url	http://eprints.usm.my/45422/1/Dr.%20Nurhidayati%20Mohamad%20Pakarul%20Razy-24%20pages.pdf
_version_	1747821507680141312

Expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR) in thyroid nodular hyperplasia and papillary thyroid carcinoma (PTC)

Similar Items